These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 35632448)

  • 41. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial.
    Xia S; Zhang Y; Wang Y; Wang H; Yang Y; Gao GF; Tan W; Wu G; Xu M; Lou Z; Huang W; Xu W; Huang B; Wang H; Wang W; Zhang W; Li N; Xie Z; Ding L; You W; Zhao Y; Yang X; Liu Y; Wang Q; Huang L; Yang Y; Xu G; Luo B; Wang W; Liu P; Guo W; Yang X
    Lancet Infect Dis; 2021 Jan; 21(1):39-51. PubMed ID: 33069281
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effectiveness of BBIBP-CorV vaccine in preventing SARS-CoV2 infection and severe outcomes in people living with multiple sclerosis: A population-based study.
    Barzegar M; Manteghinejad A; Afshari-Safavi A; Mirmosayyeb O; Nasirian M; Bagherieh S; Mazaheri S; Rahimi M; Zabeti A; Javanmard SH; Shaygannejad V
    Mult Scler Relat Disord; 2023 Mar; 71():104548. PubMed ID: 36827877
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Early assessment of the safety and immunogenicity of a third dose (booster) of COVID-19 immunization in Chinese adults.
    Zhang Y; Yang Y; Qiao N; Wang X; Ding L; Zhu X; Liang Y; Han Z; Liu F; Zhang X; Yang X
    Front Med; 2022 Feb; 16(1):93-101. PubMed ID: 35122211
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Cohort Study on the Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients With Breast Cancer; Does Trastuzumab Interfere With the Outcome?
    Joudi M; Moradi Binabaj M; Porouhan P; PeyroShabany B; Tabasi M; Fazilat-Panah D; Khajeh M; Mehrabian A; Dehghani M; Welsh JS; Keykhosravi B; Akbari Yazdi A; Ariamanesh M; Ghasemi A; Ferns G; Javadinia SA
    Front Endocrinol (Lausanne); 2022; 13():798975. PubMed ID: 35299966
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Guillain-Barré Syndrome Following the First Dose of Inactivated SARS-CoV-2 Vaccine, BBIBP-CorV.
    Wijekoon L; Sarathchandra C; Siribaddana S
    Cureus; 2023 Jan; 15(1):e33952. PubMed ID: 36819409
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
    Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
    Front Immunol; 2021; 12():793191. PubMed ID: 34975897
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neutralizing Antibodies as Predictors of Vaccine Breakthrough Infection in Healthcare Workers Vaccinated with or without a Heterologous Booster Dose: A Cohort Study during the Third COVID-19 Wave in Peru.
    Hueda-Zavaleta M; Gómez de la Torre JC; Cáceres-DelAguila JA; Muro-Rojo C; De La Cruz-Escurra N; Copaja-Corzo C; Aragón-Ayala CJ; Benítes-Zapata VA
    Vaccines (Basel); 2023 Feb; 11(2):. PubMed ID: 36851324
    [TBL] [Abstract][Full Text] [Related]  

  • 48. IgG antibody response by ELISA using Wuhan and Lambda variant antigens in BBIBP-CORV vaccinated health care workers.
    García-Mendoza M; Merino-Sarmiento N; De Lucio-Burga G; Fernández-Navarro MG; Pampa-Espinoza L; Solis-Sánchez G; Huaringa-Núñez M; Palomino-Rodríguez M; Ríos-Monteza P; Solari L
    Rev Peru Med Exp Salud Publica; 2022; 39(3):267-273. PubMed ID: 36478159
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effectiveness of BBIBP-CorV, BNT162b2 and mRNA-1273 vaccines against hospitalisations among children and adolescents during the Omicron outbreak in Argentina: A retrospective cohort study.
    González S; Olszevicki S; Gaiano A; Baino ANV; Regairaz L; Salazar M; Pesci S; Marín L; Martínez VVG; Varela T; Ceriani L; Garcia E; Kreplak N; Navarro A; Estenssoro E; Marsico F
    Lancet Reg Health Am; 2022 Sep; 13():100316. PubMed ID: 35872665
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immune responses to Sinopharm/BBIBP-CorV in individuals in Sri Lanka.
    Jeewandara C; Aberathna IS; Pushpakumara PD; Kamaladasa A; Guruge D; Wijesinghe A; Gunasekera B; Tanussiya S; Kuruppu H; Ranasinghe T; Dayarathne S; Dissanayake O; Gamalath N; Ekanayake D; Jayamali J; Jayathilaka D; Dissanayake M; Madusanka D; Jayadas TT; Mudunkotuwa A; Somathilake G; Harvie M; Nimasha T; Danasekara S; Wijayamuni R; Schimanski L; Rijal P; Tan TK; Dong T; Townsend A; Ogg GS; Malavige GN
    Immunology; 2022 Oct; 167(2):275-285. PubMed ID: 35758860
    [TBL] [Abstract][Full Text] [Related]  

  • 52. SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History.
    Drews SJ; Hu Q; Samson R; Abe KT; Rathod B; Colwill K; Gingras AC; Yi QL; O'Brien SF
    Microbiol Spectr; 2022 Feb; 10(1):e0226221. PubMed ID: 35171006
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost.
    Ai J; Zhang H; Zhang Y; Lin K; Zhang Y; Wu J; Wan Y; Huang Y; Song J; Fu Z; Wang H; Guo J; Jiang N; Fan M; Zhou Y; Zhao Y; Zhang Q; Liu Q; Lv J; Li P; Qiu C; Zhang W
    Emerg Microbes Infect; 2022 Dec; 11(1):337-343. PubMed ID: 34935594
    [No Abstract]   [Full Text] [Related]  

  • 54. Alterations of Fecal Metabolome Associated with BBIBP-CorV Vaccines against the SARS-CoV-2 Virus.
    Dong Y; Shen Y; Wang P; Jiao J; Chen M; Li J
    Front Biosci (Landmark Ed); 2023 Apr; 28(4):65. PubMed ID: 37114533
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Side Effects and Efficacy of COVID-19 Vaccines among the Egyptian Population.
    Elgendy MO; El-Gendy AO; Mahmoud S; Mohammed TY; Abdelrahim MEA; Sayed AM
    Vaccines (Basel); 2022 Jan; 10(1):. PubMed ID: 35062770
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of the humoral response induced by BBIBP-CorV vaccine by determining neutralizing antibodies in peruvian healthcare personnel.
    Soto A; Charca-Rodríguez FM; Pareja-Medina M; Fernandez-Navarro M; Altamirano-Cáceres K; Sierra Chávez E; Raraz-Vidal J; Cabezudo-Pillpe N; Velarde-Rodríguez M; Alcántara-Díaz A
    Rev Peru Med Exp Salud Publica; 2021; 38(4):493-500. PubMed ID: 35385001
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Early Effectiveness of Four SARS-CoV-2 Vaccines in Preventing COVID-19 among Adults Aged ≥60 Years in Vojvodina, Serbia.
    Petrović V; Vuković V; Marković M; Ristić M
    Vaccines (Basel); 2022 Mar; 10(3):. PubMed ID: 35335021
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Persistence of immune responses to the Sinopharm/BBIBP-CorV vaccine.
    Jeewandara C; Aberathna IS; Pushpakumara PD; Kamaladasa A; Guruge D; Wijesinghe A; Gunasekera B; Ramu ST; Kuruppu H; Ranasinghe T; Dayarathna S; Dissanayake O; Gamalath N; Ekanayake D; Jayamali J; Jayathilaka D; Dissanayake M; Jayadas TT; Mudunkotuwa A; Somathilake G; Harvie M; Nimasha T; Danasekara S; Wijayamuni R; Schimanski L; Rijal P; Tan TK; Dong T; Townsend A; Ogg GS; Malavige GN
    Immun Inflamm Dis; 2022 Jun; 10(6):e621. PubMed ID: 35634958
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Function is more reliable than quantity to follow up the humoral response to the Receptor Binding Domain of SARS- CoV-2 Spike protein after natural infection or COVID-19 vaccination.
    Sariol CA; Pantoja P; Serrano-Collazo C; Rosa-Arocho T; Armina A; Cruz L; Stone ET; Arana T; Climent C; Latoni G; Atehortua D; Pabon-Carrero C; Pinto AK; Brien JD; Espino AM
    medRxiv; 2021 Aug; ():. PubMed ID: 34100029
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Correlation of gut microbiota and metabolic functions with the antibody response to the BBIBP-CorV vaccine.
    Tang B; Tang L; He W; Jiang X; Hu C; Li Y; Zhang Y; Pang K; Lei Y; Li S; Liu S; Wang S; Yang M; Li Z; Zhao F; Yang S
    Cell Rep Med; 2022 Oct; 3(10):100752. PubMed ID: 36228621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.